Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 61.8% to $10.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $10.0 million, a 61.8% decrease, with the full-year FY2025 number at $10.0 million, down 61.8% from a year prior.
  • Non-Current Deffered Revenue was $10.0 million for Q4 2025 at Nurix Therapeutics, down from $15.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $77.7 million in Q1 2021 to a low of $10.0 million in Q4 2025.
  • A 5-year average of $37.5 million and a median of $35.2 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 75.35% in 2023, then skyrocketed 191.5% in 2024.
  • Nurix Therapeutics' Non-Current Deffered Revenue stood at $59.0 million in 2021, then plummeted by 39.05% to $36.0 million in 2022, then rose by 25.15% to $45.0 million in 2023, then plummeted by 41.79% to $26.2 million in 2024, then crashed by 61.8% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Non-Current Deffered Revenue are $10.0 million (Q4 2025), $15.2 million (Q3 2025), and $21.6 million (Q2 2025).